3.8 Review

Application of Cell, Tissue, and Biomaterial Delivery in Cardiac Regenerative Therapy

Journal

ACS BIOMATERIALS SCIENCE & ENGINEERING
Volume 7, Issue 3, Pages 1000-1021

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsbiomaterials.0c01805

Keywords

cardiac tissue engineering; ischemic heart disease; biomaterials

Funding

  1. Consejo Nacional de Ciencias y Tecnologia (CONACYT) scholarship
  2. National Sciences and Engineering Research Council of Canada (NSERC) [RGPIN-05500-2018]
  3. Canadian Institute of Heath Research (CIHR) [PJT-162440]

Ask authors/readers for more resources

Cardiovascular diseases are a leading cause of death worldwide, with ischemic heart disease being the primary cause. Cardiac regenerative therapy aims to repair and refunctionalize damaged heart tissue, offering potential solutions to the challenges posed by CVD.
Cardiovascular diseases (CVD) are the leading cause of death around the world, being responsible for 31.8% of all deaths in 2017 (Roth, G. A. et al. The Lancet 2018, 392, 1736-1788). The leading cause of CVD is ischemic heart disease (IHD), which caused 8.1 million deaths in 2013 (Benjamin, E. J. et al. Circulation 2017, 135, e146-e603). IHD occurs when coronary arteries in the heart are narrowed or blocked, preventing the flow of oxygen and blood into the cardiac muscle, which could provoke acute myocardial infarction (AMI) and ultimately lead to heart failure and death. Cardiac regenerative therapy aims to repair and refunctionalize damaged heart tissue through the application of (1) intramyocardial cell delivery, (2) epicardial cardiac patch, and (3) acellular biomaterials. In this review, we aim to examine these current approaches and challenges in the cardiac regenerative therapy field.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available